{"contentid": 488668, "importid": NaN, "name": "Despite pandemic R&D remains robust, finds industry analyst", "introduction": "Industry analyst IQVIA has conducted research into global R&D trends in the pharmaceutical industry, finding that, notwithstanding significant disruption, activity has been at an all-time high during the pandemic.", "content": "<p><span style=\"font-weight: 400;\">Industry analyst </span><a href=\"http://www.iqviainstitute.org/\"><span style=\"font-weight: 400;\">IQVIA</span></a><span style=\"font-weight: 400;\"> has conducted research into global R&amp;D trends in the pharmaceutical industry, finding that, notwithstanding significant disruption, activity has been at an all-time high during the pandemic.</span></p>\n<p><span style=\"font-weight: 400;\">The researchers found that there was some reprioritization of clinical trial activity during 2020 due to COVID-19, but new sources of funding and strategic transactions kept overall levels buoyant.</span></p>\n<p><span style=\"font-weight: 400;\">R&amp;D was particularly active in the area of oncology, according to the report, which was prepared by IQVIA&rsquo;s Institute for Human Data Science.&nbsp;&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">Executive director Murray Aitken said: &ldquo;The growth in research and development driven by new oncology drugs, new funding and strategic investments is a testament to the resilience and strength of the innovative, global biopharmaceutical industry.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">He added: &ldquo;Faced with significant disruptions and the need to reprioritize research and development, the global life sciences industry has demonstrated its ability to meet and even exceed expectations for new and better lifesaving therapies and vaccines.&rdquo;&nbsp;&nbsp;</span></p>\n<h2><strong>R&amp;D in 2020</strong></h2>\n<p><span style=\"font-weight: 400;\">Researchers found that clinical development productivity increased slightly in 2020 but remains at historically low levels due to high trial durations, complex disease targets and falling success rates.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">IQVIA said that greater use of evidence-based approaches for the improvement of trial design could yield improvements over time.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">On the overall R&amp;D pipeline, there was continued late-stage growth, with a 43% increase since 2015 driven by oncology candidates in particular.</span></p>\n<p><span style=\"font-weight: 400;\">Meanwhile, growth in the early-stage pipeline and for next-generation biotherapeutics remained static.</span></p>\n<p><span style=\"font-weight: 400;\">Funding for research and development increased significantly in 2020, &ldquo;reflecting a strong focus on innovative pathways and approaches to discover and develop novel therapeutics,&rdquo; the report said.</span></p>\n<p><span style=\"font-weight: 400;\">In addition, sustained investment and efforts to discover and develop innovative medicines led to a record 66 new drugs globally with success in oncology and rare diseases, in addition to coronavirus vaccines.</span></p>", "date": "2021-05-19 13:00:00", "meta_title": NaN, "meta_keywords": "industry, research, global, analyst, pandemic, development, oncology, IQVIA, significant, activity, high, funding, trial, growth, innovative, remains, find", "meta_description": "Industry analyst IQVIA has conducted research into global R&D trends in the pharmaceutical industry, finding that notwithstanding significant disruption activit", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "2021-05-19 13:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-19 09:18:59", "updated": "2021-05-19 13:45:02", "access": NaN, "url": "https://www.thepharmaletter.com/article/despite-pandemic-r-d-remains-robust-finds-industry-analyst", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "2020_biotech_lab_vial_research_big.jpg", "image2id": "2020_biotech_lab_vial_research_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology, Pharmaceutical", "therapy area_tag": "Infectious diseases, Oncology, Rare diseases, Vaccines", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "Global", "company_tag": "IQVIA INC.", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-19 13:00:00"}